Navigation Links
Jamming in tumors

This news release is available in German.

Just like healthy cells, tumour cells need nutrients and oxygen in order to survive. For this reason, a tumour of a certain size has to ensure that it is connected to the blood circulation. In doing this, it is supported by cells of the innate immune system, the neutrophil granulocytes or brief neutrophils, which are supposed to protect the body against pathogens.

Neutrophils normally circulate in the blood untilattracted by so-called chemokinesthey enter the tissue where they ingest and destroy intruding pathogens. In addition, these cells are able to trigger the formation of blood vessels. Presumably, this is how they help to repair tissue which has been destroyed by inflammation. However, neutrophils are also able to enter cancer tissue and contribute to its connection to the blood supply. This is probably the reason why detection of numerous neutrophils in a tumour is a sign of unfavourable patient prognosis.

Interferon-beta (IFN-beta) is used as a treatment for some tumours such as melanomas and leukaemia. Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, had shown recently that this messenger molecule can interfere with cancer growth by inhibiting the formation of new blood vessels. However, the way it does so remained a puzzle.

Now, researchers have succeeded in revealing the effect of IFN-beta on migration of pro-tumour neutrophils. "We wanted to understand why IFN-beta prevents the neutrophils from entering the tumour," says Dr Jadwiga Jablonska-Koch, scientist in the "Molecular Immunology" department at the HZI. "This would be the way for physicians to improve existing therapies and choose appropriate treatment for the individual patient."

To this end, the scientists followed the interaction between the cells. Messenger molecules such as chemokines are a means of communication frequently used for this purpose. They are produced by cells and bind to correspondingly shaped surface receptors. In the case of neutrophils, this is the receptor called CXCR2. It binds the chemokines CXCL1, CXCL2 and CXCL5. "We have seen that the concentration of the chemokines in the bone marrow, where the neutrophils originate, is low," says Dr Siegfried Weiss, head of the department in which Jablonska-Koch works. "On the other hand, we find a high concentration in the tumour, which attracts the neutrophils." Neutrophils migrate along the chemokine gradient into the tumour and once there, they themselves release the same chemokines in order to attract other neutrophils to obtain more support.

IFN-beta interferes with this communication: it makes the cells in the tumour produce fewer chemokines and no chemokine gradient is formed. "That way, fewer neutrophils enter the cancer tissue and fewer new blood vessels are formed," says Jablonska-Koch. "The tumour is not effectively connected to the vital blood supply and cannot grow efficiently." For that reason it is of therapeutical benefit to administer IFN-beta additionally. "We now better understand why IFN-beta helps in some cancers and that it is an important part of the body's own system for combating tumours," says Weiss. Their findings could help physicians to assess which patients might profit from administering IFN-beta and when neutrophils ought to be an objective of cancer therapy.


Contact: Birgit Manno
Helmholtz Centre for Infection Research

Related biology news :

1. Multiple myeloma study uncovers genetic diversity within tumors
2. Stopping tumors in their path
3. Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy
4. Gene promotes 1 in 100 of tumors
5. A hallmark for the development of testicular tumors found in the aberrant regulation of small non-coding RNA
6. Copper intake makes tumors breathe
7. Microbes in the gut help determine risk of tumors
8. Researchers Able to Identify that Benign Tumors from Use of Oral Contraceptive Have a Greater Chance of Becoming Malignant
9. Stealth nanoparticles lower drug-resistant tumors defenses
10. Why tumors become drug-resistant
11. RI Hospital: Absence of specific enzyme in cartilage can lead to benign tumors in mice
Post Your Comments:
Related Image:
Jamming in tumors
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: